LY4086940

In plain English

LY4086940 is a development code, the label a company uses while a medicine is still being tested. A name is given only if the medicine gets far enough to be approved. This code belongs to Eli Lilly, the company behind Zepbound and Foundayo. Lilly's trial records show that LY4086940 is taken by mouth. A phase 1 trial has tested it in healthy adults and in adults with overweight, obesity or type 2 diabetes, and a phase 2 trial is registered to test weight loss. For what Lilly's LY numbers mean and which ones match a public name, see Lilly's LY numbers explained.

Lilly's own slides give LY4086940 a second name. Lilly's fourth-quarter 2025 earnings slides, presented on the February 4, 2026 call, list the phase 1 study of LY4086940 under the program name "GGG Tri-Agonist III" on slide 51, and its pipeline chart on slide 18 shows that name among the cardiometabolic programs (Lilly Q4 2025 slides). The third-quarter 2025 slides show the same entry (Q3 2025 slides 16 and 45). That is a program label, not a brand or generic name. A triple agonist is one medicine built to switch on three hormone receptors at once.

Which three is the open question. A slide from Lilly's 2025 ADA investor event lists an "oral GGG peptide" and labels it a GLP-1, GIP and glucagon agonist, the same label it gives retatrutide, which is a weekly injection (ADA slide 8). GIP, GLP-1 and glucagon are the three targets. No slide says outright that the oral GGG peptide is the same program as LY4086940, and the trial records do not state targets. The link comes from a write-up on PeptideBlog.net, which also cites patent filings, so the Atlas treats the three receptors and the peptide description as reported, not confirmed.

What is certain is short. A phase 1 safety study of 219 people has finished. A phase 2 weight-loss study of 460 adults is registered and listed to start in November 2026, and on October 26, 2026 its record listed 46 study sites, 39 in the United States and 7 in Argentina. A site list shows where Lilly plans to enroll, not that anyone has been dosed. Neither study has published results. So anything said about how much weight LY4086940 takes off, what dose to use or what side effects it causes is not coming from a published trial. Products sold online under this code are not approved medicines. Because the exact molecule has not been publicly confirmed, a lab purity report alone cannot show that a product is LY4086940.

EloralintideResearch.com has a separate reading of the same two trial records, with an evidence label on each statement: LY4086940: what its two trial records show.

PeptideBlog.net lays out the public record in date order, from the 2024 patent publications to the October 2026 phase 2 registration: LY4086940 timeline.

LY4086940 at a glance

LY4086940 and the name "GGG Tri-Agonist III"

Lilly's fourth-quarter 2025 earnings slides, presented on the February 4, 2026 call, use the program name GGG Tri-Agonist III in two places. The pipeline chart on slide 18 lists it among Lilly's cardiometabolic programs. The early-phase trials table on slide 51 lists the phase 1 study NCT06945419 under that name, described as a trial of LY4086940 in healthy people and in people with overweight or obesity, with or without type 2 diabetes (Lilly Q4 2025 slides). The third-quarter 2025 slides, presented on the October 30, 2025 call, show the same entry on slides 16 and 45 (Lilly Q3 2025 slides). That ties the two names to the same program.

The slides do not give the molecule, the dose or any results, and neither do the trial records. A tri-agonist is one medicine built to act on three hormone receptors at once. Slide 8 of Lilly's 2025 ADA investor event separately lists an oral GGG peptide as a GLP-1, GIP and glucagon agonist (ADA slide 8), which suggests the letters GGG refer to those three receptors, but no slide spells that out or says that entry is LY4086940. The table below keeps what Lilly shows apart from what is only reported.

What the two trial records show

Both trials are listed on ClinicalTrials.gov, the U.S. registry where sponsors post studies. Lilly is the sponsor of each. The arm descriptions give no dose amounts, and neither record has results.

Source: the two ClinicalTrials.gov records. Phase 2 dates are the sponsor's estimates and can change. The phase 2 trial runs under Lilly's chronic weight management master protocol, NCT06143956.

What is confirmed and what is only reported

Most of what circulates about LY4086940 mixes registry facts with descriptions from other sources. This table keeps them apart.

LY4086940 and retatrutide

The two names are often mentioned together because the reported targets overlap. Here is what the evidence supports for each today.

Where LY4086940 sits among Lilly's weight-loss medicines

Lilly now has approved and investigational weight-loss medicines in several forms. This table covers only the ones the Atlas profiles. Lilly may have others.

See the pipeline for every registered weight-management trial the Atlas tracks, and weight-loss pills for how the approved pills compare. Other Lilly codes with no public name are listed in Lilly's LY numbers explained.

How to read an early trial

A phase 1 trial is the first time a new medicine is tested in people. It is usually small and short, and its main job is to look for safety problems and learn how the body handles the medicine. Weight numbers from a phase 1 trial, when they are shown at all, come from a few weeks of treatment and say little about what a longer course would do. The LY4086940 phase 1 record lists serious side effects as its main measure and blood levels as its secondary measures. It does not list weight.

A phase 2 trial is larger and usually compares several doses with placebo. The registered LY4086940 trial has nine active arms, named Dose 1 to Dose 6 with extra titration schedules for Dose 3 and Dose 6, plus a placebo arm. The registry gives no amounts, so the numbers behind those labels are unknown.

A registration is a plan, not a result. Start and end dates in a registry are estimates and they move. A listed start of November 2026 does not show that anyone has taken a dose. Results usually appear later in the registry, at a medical meeting or in a journal, and the Atlas shows trial numbers only once they are published. For how to compare numbers between trials, see the beginner guide and the trial results page.

If you see LY4086940 for sale

LY4086940 is not approved and is not available as a medicine. It is given only to people enrolled in Lilly's registered trials. Products offered online under the code, under the name GGG Tri-Agonist III, or described as an oral triple agonist, are not FDA-approved medicines, and the FDA has not reviewed what they contain.

Two facts make such products hard to judge. The exact molecule has not been publicly confirmed, so there is no public reference for a lab to test a product against. And a purity percentage describes how much of a sample is one substance. It does not by itself say which substance that is. The Atlas does not list or rate sellers. For how the rules around unapproved peptides are changing, see the peptide policy tracker and compounded versus brand-name medicines.

What would change the picture

• Results from the phase 1 trial, posted in the registry, shown at a medical meeting or published in a journal.
• The phase 2 trial changing from not yet recruiting to recruiting, and later reporting weight results at week 32.
• A Lilly document that names the molecule and its receptors.
• A phase 3 registration or an FDA filing. The Atlas found neither.

Brand names and products

A generic name identifies the drug itself. A brand name identifies one company's product. One drug can come in several products with different forms and approved uses, so the brand name often tells you more about what a prescription is for.

No brand name is recorded for this medicine because there is no approved product.

How it works

The trial records do not say how LY4086940 works. Lilly's fourth-quarter and third-quarter 2025 slides list it under the program name GGG Tri-Agonist III, so Lilly itself calls it a tri-agonist, meaning one medicine aimed at three receptors. Those slides do not name the receptors. A slide from Lilly's 2025 ADA investor event lists an oral GGG peptide as a GLP-1, GIP and glucagon agonist, but no slide ties that entry to LY4086940 by name. A write-up on PeptideBlog.net links the two and describes an oral peptide that activates the GIP, GLP-1 and glucagon receptors. It also cites two patent publications on tri-receptor agonists, and it says no link between any patent example and LY4086940 has been shown. The Atlas cannot confirm the receptor list or the peptide description. If the list is correct, the medicine would aim at the same three receptors as retatrutide. How an oral form is made to work, what formulation is used and how much reaches the blood have not been published.

Forms and approval status

What the trials found

No trial figures have been added to this atlas for this medicine yet.

Safety

Boxed warning and label notes

• LY4086940 oral (investigational): Not applicable. Not approved.

Warnings labels describe

• Not approved, so no official label exists. No safety results from any LY4086940 trial have been published.
• Trial participants are screened and monitored. Nothing is known about LY4086940 outside a supervised trial, and a product sold under this code cannot be assumed to contain it.

Quick answers

What is LY4086940?

LY4086940 is the development code for an investigational oral medicine from Eli Lilly. Lilly's slides list it under the program name GGG Tri-Agonist III. It has finished a phase 1 safety trial and has a phase 2 weight-loss trial registered. It has no brand name and is not approved anywhere.

What is GGG Tri-Agonist III?

GGG Tri-Agonist III is the program name Eli Lilly uses in its fourth-quarter and third-quarter 2025 earnings slides for the compound whose phase 1 study is a trial of LY4086940. It is an internal program label, not a brand or generic name. A tri-agonist is one medicine built to act on three hormone receptors at once. A Lilly ADA 2025 slide lists an oral GGG peptide as a GLP-1, GIP and glucagon agonist, which suggests the three Gs refer to those receptors, but no slide says so or names LY4086940. It is not approved and no results are public.

Is LY4086940 a peptide?

Lilly's ADA 2025 investor slide lists an "oral GGG peptide", and a write-up on PeptideBlog.net links it to LY4086940. Neither trial record says LY4086940 is a peptide and the Atlas found no published structure, so treat it as unconfirmed. A peptide is a short chain of amino acids.

Is LY4086940 an oral triple agonist?

Lilly's own slides list it under the program name GGG Tri-Agonist III, so Lilly does call it a tri-agonist, one medicine aimed at three receptors. A separate Lilly slide lists an oral GGG peptide as a GLP-1, GIP and glucagon agonist, the same targets as retatrutide. No slide says in so many words that this entry is LY4086940 and the trial records do not state targets, so the list of three receptors remains reported, not confirmed.

Is LY4086940 the same as retatrutide?

Nothing public shows that. Retatrutide is Lilly's code LY3437943, a weekly injection with phase 3 results published. LY4086940 is a different code that Lilly registers in separate trials, and its records describe it as taken by mouth. Two medicines can share target receptors and still be different molecules.

How is LY4086940 different from Foundayo (orforglipron)?

Foundayo is orforglipron, Lilly's approved daily pill. It is a small molecule that switches on the GLP-1 receptor and is not a peptide. LY4086940 is a separate investigational oral medicine with a different code, and its targets and structure are not confirmed. Foundayo has an FDA label and published phase 3 results. LY4086940 has neither.

What is the LY4086940 dosage?

No dose has been published. The phase 2 record names its arms Dose 1 to Dose 6, with extra titration schedules for two of them, and gives no amounts. The Atlas does not give dosing instructions for any medicine. For an approved medicine, the dose comes from its label and a prescriber.

Has LY4086940 been tested in humans?

Yes. A phase 1 trial (NCT06945419) enrolled 219 adults and finished on August 5, 2026. It tested oral doses in healthy adults and in adults with overweight, obesity or type 2 diabetes, and one single intravenous dose in healthy adults. No results are posted.

What are the side effects of LY4086940?

They are unknown. No results from any LY4086940 trial have been published or posted. The phase 1 trial's main measure is the number of people with a serious side effect judged related to the drug, so safety is what it was built to check, but the findings are not public.

Is LY4086940 approved or available?

No. It is investigational and is given only inside clinical trials. The Atlas found no announced FDA filing for it.

Can you buy LY4086940?

Not as an approved medicine. Products sold online under the code are not FDA-approved, and because the exact molecule has not been publicly confirmed, a lab report cannot by itself show that a product is LY4086940.

When will LY4086940 results come out?

The Atlas found no announced date. The phase 1 trial finished in August 2026 and has no posted results. The phase 2 trial is listed to start in November 2026, with its main measure at week 32 and primary completion listed as January 2028.

Where can I read the official trial records?

ClinicalTrials.gov lists them: NCT06945419 for phase 1 and NCT07890376 for phase 2. The phase 2 trial runs under Lilly's chronic weight management master protocol.

What is still unknown

• The exact molecule: its sequence, structure, weight, and whether it is a peptide. None is given in the trial records, and the Atlas did not find a published one.
• Which three receptors it acts on. Lilly's slides call the program a tri-agonist and list an oral GGG peptide as a GLP-1, GIP and glucagon agonist, but the Atlas found no Lilly document that says that entry is LY4086940.
• How the oral form is made, what the doses are, how often it would be taken, and whether food or timing matter.
• How much it lowers body weight, if at all, and how that compares with retatrutide, orforglipron or tirzepatide.
• Side effects, safety, and what happens after treatment stops.
• Whether it will move to phase 3 or be filed with the FDA. The Atlas found no announced plan.

Related medicines

Compare LY4086940 with other medicines

Open the comparison tool with LY4086940 selected. It puts forms, brand names, approval status and trial figures in one table. The figures come from different studies, so they are not head-to-head results unless the table says so.

Follow Eli Lilly

See every Lilly weight-loss and diabetes medicine, its trials, recent company statements and upcoming events in the Eli Lilly obesity and diabetes tracker.